TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00401739

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CSL360
Description: Weekly IV Infusion. Dose escalation study.
Study: NCT04142528

Intervention type: DEVICE
Intervention: ParkinPal
Description: Wear and periodic recording of motion data during daily wear
Study: NCT02265861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCG
Study: NCT03042182

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Oral therapeutic vaccine V3-X to treat cholangiocarcinoma
Description: One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
Study: NCT00779922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Study: NCT01591525

Intervention type: BEHAVIORAL
Intervention: Education on risk factors for Type II Diabetes
Description: one-on-one education provided by a nurse practitioner or physician

Intervention type: BEHAVIORAL
Intervention: Education on risk factors for Type II Diabetes
Description: one-on-one education provided by a nurse practitioner or physician

Intervention type: BEHAVIORAL
Intervention: Education on Type II Diabetes
Description: one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
Study: NCT04213027

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: native tissue repair procedures with conventional surgical instruments
Description: Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: native tissue repair procedures with conventional surgical instruments
Description: Sacrospinous ligament fixation (SSLF): treatment for apical prolapse with vaginal fornix suspended to sacrospinous ligament; Ischial spinous fascia fixation (ISFF): treatment for apical prolapse with vaginal fornix suspended to ischial spinous fascia (ISFF).
Study: NCT03599037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICOUGH Recovery App v2.0
Description: The app has pre-set auditory, visual reminders, in the form of push notifications, that remind participants to use the incentive spirometer and ambulate around the hospital at time intervals recommended by the ICOUGH protocol. The app benchmarks the level of adherence to that of other subjects involved in the study via the My Summary page, and this visual anonymous comparison further motivates adherence to the ICOUGH protocol.
Study: NCT00902187

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg

Intervention type: DRUG
Group type: OTHER
Intervention: Fesoterodine
Description: A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
Study: NCT00795249

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: smoking cessation
Description: After baseline examination, the group is asked to quit smoking for 2 weeks.
Study: NCT01643525

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.

Intervention type: DEVICE
Intervention: Nautilus NeuroWaveTM System
Description: Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
Study: NCT02933632

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy-SAP
Description: * Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;~* Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;~* Day 4 and other days) Patients repeated the gait training until the discharge date.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical Therapy-ARP
Description: * Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;~* Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;~* Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;~* Day 2) Patients repeated three times the day 1-3°approach;~* Day 3) Patients repeated three times the day 1-3°approach.
Study: NCT02004951

Intervention type: DEVICE
Group type: OTHER
Intervention: Misago RX

Intervention type: DEVICE
Group type: OTHER
Intervention: Zilver PTX
Study: NCT00072358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-GD2 murine IgG3 monoclonal antibody 3F8
Description: The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-GD2 murine IgG3 monoclonal antibody 3F8
Description: The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over \~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started \~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive \~10 cycles.
Study: NCT01534013

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The Imperial College Closed-Loop Insulin Delivery System
Description: The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open loop
Description: glucose sensor and pump
Study: NCT01085786

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 14-day sequential treatment
Description: * 14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days~* 14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 14-day hybrid treatment
Description: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
Study: NCT00136409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate
Description: 400mg orally once daily until disease progression or unacceptable side effects
Study: NCT03889665

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suspension training
Description: Nine sessions of suspension training The suspension device will be TRX (R) The intervention will be administered in work:rest intervals (2:1) A global training approach will seek to train lower limbs, upper body and core musculature
Study: NCT03372850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HIP1601
Description: Test Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705
Description: Reference Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1705
Description: Reference Drug
Study: NCT05829642

Intervention type: BEHAVIORAL
Intervention: Enhanced Care Management
Description: ECM aims to enable primary health care providers to coordinate care for patients with complex medical needs. It involves the close coordination of services across all treatment modalities and clinical team members, including primary care physicians, specialists, pharmacists, and other healthcare professionals. Providers undertake:~Comprehensive care planning: A comprehensive care plan is developed and updated by all members of the patient's healthcare team, including their primary care physician, specialist, and other providers, to ensure that all aspects of treatment are addressed.~Proactive outreach: Outreach activities, such as phone calls, home visits, and other forms of contact with the patient and their family are also used to promote patient engagement in health management~Monitoring: Close monitoring of patients and their health conditions is essential to ensure that treatments are effective and that any adverse effects are quickly identified and addressed
Study: NCT01379573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
Study: NCT02794142

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: renal transplantation

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Study: NCT02247245

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivabradine
Description: Ivabradine 7.5mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Description: Pacemaker base rate alteration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00744211

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1mg/kg sitaxsentan sodium
Description: 1mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2mg/kg sitaxsentan sodium
Description: 2mg/kg sitaxsentan sodium (intravenous bolus) performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Intravenous bolus performed immediately before separation from cardiopulmonary bypass and again at 12 hours after cardiopulmonary bypass.
Study: NCT04344301

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Audio recording
Description: The investigators will audio record the visits of patients in the intervention group. An RA will enter the exam room and begin the recording with the patient's permission. The patient and clinician can choose to stop or start the recording at any time. Once the visit is complete, the RA will enter the room, turn off the recording, and bring the patient to a private room where the RA will follow standardized instructions demonstrating how to access recordings. Patient access to recordings will be possible via a secure web-based platform. Patients will also receive reminders to listen to their recordings.
Study: NCT02488499

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coping Power
Description: 15 sessions of concurrent parent and child group treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individualized Treatment
Description: 15 sessions of individualized child and parent treatment
Study: NCT02336841

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as usual + Recovery MANTRA
Description: Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual + feedback
Description: Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
Study: NCT04409899

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood tests
Description: RT-PCR, D-dimer, CRP, procalcitonin, ferritin, complete haemogram
Study: NCT02577744

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Ventilation
Description: Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Noninvasive Ventilation
Description: Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Positive Air Pressure
Description: EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Expiratory Positive Air Pressure
Description: EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
Study: NCT00312221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxycodone immediate-release
Description: Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
Study: NCT03612362

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Improved Injera Baking Biomass Stove
Description: Replacing of the Ethiopian traditional Injera baking biomass stove with improved baking biomass stove, the well-known commercially distributed type of baking stove in Ethiopia, will be the intervention for this study. Control HHs will continue to use the traditional baking biomass stove. Concerning intervention duration, since the life span of the Ethiopian improved baking stove is about 5 years, the length of the intervention period will be one year to account for seasonal factors that have major effect on both ARI incidence \& HAP level in Ethiopia as well as to maintain a balance between achieving a sufficiently long follow-up period for outcome measurements \& suitably short follow-up period to decrease attrition.
Study: NCT04338373

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain)
Description: nightly instillations of 0.01% Atropine sulfate solution in Comfort Drops (AVIZOR S.A., Spain) in both eyes for 12 months
Study: NCT02179879

Intervention type: OTHER
Intervention: Video validation
Description: Video taping of anaesthetist (experts and novices) perfoming labor epidural.
Study: NCT02403362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO-018B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO-018B

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPO-018B
Study: NCT04373954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Forgiveness Therapy
Description: The Forgiveness Therapy model mainly includes four stages: uncovering, decision, work and deepening. The book 8 Keys to Forgiveness (2015, a forgiveness therapy manual authored by Dr. Enright) is the basis for the therapy as a way to ensure that the treatment is uniformly founded on the forgiveness process developed at the University of Wisconsin-Madison.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Forgiveness Therapy
Description: The Forgiveness Therapy model mainly includes four stages: uncovering, decision, work and deepening. The book 8 Keys to Forgiveness (2015, a forgiveness therapy manual authored by Dr. Enright) is the basis for the therapy as a way to ensure that the treatment is uniformly founded on the forgiveness process developed at the University of Wisconsin-Madison.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carey Guides
Description: The Carey Guides is a primary educational program deliberately chosen and approved by the Department of Corrections in Wisconsin, in which all inmates are encouraged (not required) to complete as they work toward custody reduction. Some aspects emphasized in it include anti-social thinking, emotional regulation, moral reasoning, and so on. It is the basis for the control group therapy as a way to ensure that the treatment has a uniform process as it is taught in the Department of Corrections (DOC) prison system.
Study: NCT02771314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9291
Description: AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
Study: NCT01961375

Intervention type: DRUG
Intervention: Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)
Description: Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
Study: NCT02131675

Intervention type: DIETARY_SUPPLEMENT
Intervention: Boost shake
Description: Blood draw after mixed-meal consumption
Study: NCT03419338

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift
Description: Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sinus lift
Description: Using a lateral access, the Schneider membrane will be elevated using curettes allowing the insertion of graft material.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical alveolus
Description: Using a round diamond bur, a surgical alveolus will be created on an toothless ridge region.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inorganic bovine bone + newly forming bone
Description: Maxillary sinus lift will be done with inorganic bovine bone associated with newly forming bone. The newly forming bone will be collected from surgical alveolus previous prepared.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inorganic bovine bone
Description: Maxillary sinus lift will be done with inorganic bovine bone.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen membrane
Description: At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen membrane
Description: At the end of the sinus lift, a collagen membrane will be used to obliterate the graft inside the maxillary sinus.
Study: NCT04534491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxybutynin (Oxytrol, BAY839380)
Description: Oxybutynin transdermal patch, 3.9 mg daily (Oxytrol Transdermal System)
Study: NCT03000179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab through a vein once every 2 weeks
Study: NCT00578110

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma Diagnosis, Name: Neucodia
Description: Sensitivity and Specificity

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glaucoma Diagnosis, Name: Neucodia
Description: Sensitivity and Specificity

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glaucoma Diagnosis, Name: Neucodia
Description: Sensitivity and Specificity
Study: NCT01236105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: Administered orally (po), once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: Administered orally (po), once.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2624803
Description: Administered orally (po), once.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activated Charcoal
Description: Administered po
Study: NCT01954186

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous & intramuscular oxytocin
Description: intravenous or intramuscular 10 iu oxytocin

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: after delivery of the fetus & when anterior shoulder seen
Description: oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
Study: NCT01135862

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: platelets
Description: 6 packs of platelets will be administered

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: platelets
Description: 6 packs of platelets will be administered
Study: NCT02695433

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Active
Description: Active Treatment Diet Plan

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Control Diet Plan
Study: NCT02170779

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spasticity: Take Control
Description: 4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: 2 visits: baseline followed by usual care of brochure for stretching then outcome measures